Article
Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing.
Nature biotechnology - 1 Sept 2021
Xiao Wenming, Ren Luyao, Chen Zhong, Fang Li Tai, Zhao Yongmei, Lack Justin, Guan Meijian, Zhu Bin, Jaeger Erich, Kerrigan Liz, Blomquist Thomas M, Hung Tiffany, Sultan Marc, Idler Kenneth, Lu Charles, Scherer Andreas, Kusko Rebecca, Moos Malcolm, Xiao Chunlin, Sherry Stephen T, Abaan Ogan D, Chen Wanqiu, Chen Xin, Nordlund Jessica, Liljedahl Ulrika, Maestro Roberta, Polano Maurizio, Drabek Jiri, Vojta Petr, Kõks Sulev, Reimann Ene, Madala Bindu Swapna, Mercer Timothy, Miller Chris, Jacob Howard, Truong Tiffany, Moshrefi Ali, Natarajan Aparna, Granat Ana, Schroth Gary P, Kalamegham Rasika, Peters Eric, Petitjean Virginie, Walton Ashley, Shen Tsai-Wei, Talsania Keyur, Vera Cristobal Juan, Langenbach Kurt, de Mars Maryellen, Hipp Jennifer A, Willey James C, Wang Jing, Shetty Jyoti, Kriga Yuliya, Raziuddin Arati, Tran Bao, Zheng Yuanting, Yu Ying, Cam Margaret, Jailwala Parthav, Nguyen Cu, Meerzaman Daoud, Chen Qingrong, Yan Chunhua, Ernest Ben, Mehra Urvashi, Jensen Roderick V, Jones Wendell, Li Jian-Liang, Papas Brian N, Pirooznia Mehdi, Chen Yun-Ching, Seifuddin Fayaz, Li Zhipan, Liu Xuelu, Resch Wolfgang, Wang Jingya, Wu Leihong, Yavas Gokhan, Miles Corey, Ning Baitang, Tong Weida, Mason Christopher E, Donaldson Eric, Lababidi Samir, Staudt Louis M, Tezak Zivana, Hong Huixiao, Wang Charles, Shi Leming
Abstract excerpt
Clinical applications of precision oncology require accurate tests that can distinguish true cancer-specific mutations from errors introduced at each step of next-generation sequencing (NGS). To date, no bulk sequencing study has addressed the effects of cross-site reproducibility, nor the biological, technical and computational factors that influence variant identification. Here we report a systematic...
Read the complete abstract on PubMed